PMID- 11091279
OWN - NLM
STAT- MEDLINE
DCOM- 20001214
LR  - 20190513
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 122
IP  - 2
DP  - 2000 Nov
TI  - Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis.
PG  - 227-31
AB  - Primary biliary cirrhosis is an autoimmune disease of the liver in which T helper 
      1 cytokines predominate over those of T helper 2 in the pathogenesis. 
      Interleukin- 18 (IL-18), for which the gene was recently cloned, is a novel T 
      helper 1 cytokine, which augments interferon-gamma production. We designed this 
      study to clarify the role of IL-18 in primary biliary cirrhosis and to examine 
      whether serum IL-18 level can be a prognostic indicator for the disease. Serum 
      IL-18 levels were measured using an enzyme linked immuno sorbent assay with mouse 
      monoclonal antibodies. Twenty-two healthy volunteers, 31 patients with primary 
      biliary cirrhosis (Scheuer's stage I, 13; II, 10; and IV, 8), 20 patients with 
      autoimmune hepatitis, 11 patients with virus-related liver cirrhosis and six 
      patients with obstructive jaundice were enrolled. Significant differences of 
      serum IL-18 levels were observed between patients with Scheuer's stage IV and 
      those with stage I, or II, virus-related liver cirrhosis and obstructive jaundice 
      (P < 0.05). The IL-18 levels in primary biliary cirrhosis increased according to 
      the disease progression, and fell promptly after living-related liver 
      transplantation. Moreover, serum IL-18 levels in primary biliary cirrhosis were 
      correlated with serum bilirubin concentrations and the Risk scores of the Mayo 
      Clinic prognostic model for the disease. The IL-18 levels observed in patients 
      with autoimmune hepatitis were also elevated, and correlated with the activity of 
      the disease. These results indicate that serum interleukin-18 levels reflect the 
      severity of primary biliary cirrhosis, the activity of autoimmune hepatitis, and 
      may be an additive prognostic indicator in primary biliary cirrhosis.
FAU - Yamano, T
AU  - Yamano T
AD  - First Department of Internal Medicine, Okayama University Medical School, 
      Okayama-city, Japan.
FAU - Higashi, T
AU  - Higashi T
FAU - Nouso, K
AU  - Nouso K
FAU - Nakatsukasa, H
AU  - Nakatsukasa H
FAU - Kariyama, K
AU  - Kariyama K
FAU - Yumoto, E
AU  - Yumoto E
FAU - Kobayashi, Y
AU  - Kobayashi Y
FAU - Yamamoto, K
AU  - Yamamoto K
FAU - Iwagaki, H
AU  - Iwagaki H
FAU - Yagi, T
AU  - Yagi T
FAU - Tanimoto, T
AU  - Tanimoto T
FAU - Kurimoto, M
AU  - Kurimoto M
FAU - Tanaka, N
AU  - Tanaka N
FAU - Tsuji, T
AU  - Tsuji T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Interleukin-18)
RN  - 187348-17-0 (Interleukin-12)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Autoimmune Diseases/immunology
MH  - Case-Control Studies
MH  - Cholestasis/immunology
MH  - Female
MH  - Hepatitis/immunology
MH  - Humans
MH  - Interferon-gamma/biosynthesis/blood
MH  - Interleukin-12/blood
MH  - Interleukin-18/*blood
MH  - Liver Cirrhosis/immunology
MH  - Liver Cirrhosis, Biliary/*immunology/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
PMC - PMC1905768
EDAT- 2000/11/25 11:00
MHDA- 2001/02/28 10:01
PMCR- 2001/11/01
CRDT- 2000/11/25 11:00
PHST- 2000/11/25 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/11/25 11:00 [entrez]
PHST- 2001/11/01 00:00 [pmc-release]
AID - cei1356 [pii]
AID - 10.1046/j.1365-2249.2000.01356.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2000 Nov;122(2):227-31. doi: 10.1046/j.1365-2249.2000.01356.x.